An efficient multistep ligand-based virtual screening approach for GPR40 agonists

[1]  Malgorzata N. Drwal,et al.  Combination of ligand- and structure-based methods in virtual screening. , 2013, Drug discovery today. Technologies.

[2]  M. Ferdaoussi,et al.  Free Fatty Acid Receptor 1: A New Drug Target for Type 2 Diabetes? , 2012 .

[3]  B. Hudson,et al.  Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. , 2012, Journal of medicinal chemistry.

[4]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[5]  A. Hamza,et al.  Ligand-Based Virtual Screening Approach Using a New Scoring Function , 2012, J. Chem. Inf. Model..

[6]  Masahiro Ito,et al.  Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. , 2012, Journal of medicinal chemistry.

[7]  Toshimasa Tanaka,et al.  Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes. , 2012, Journal of medicinal chemistry.

[8]  Yi-jun Zhou,et al.  Linoleic acid activates GPR40/FFA1 and phospholipase C to increase [Ca2+]i release and insulin secretion in islet beta-cells. , 2012, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[9]  Masahiro Ito,et al.  Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists. , 2012, Journal of medicinal chemistry.

[10]  Ying Sun,et al.  AMG 837: a potent, orally bioavailable GPR40 agonist. , 2012, Bioorganic & medicinal chemistry letters.

[11]  K. Takeuchi,et al.  TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats , 2011, Journal of Pharmacology and Experimental Therapeutics.

[12]  L. Pardo,et al.  Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. , 2011, Journal of medicinal chemistry.

[13]  A. Howard,et al.  3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists. , 2011, Bioorganic & medicinal chemistry letters.

[14]  Shao-Yong Lu,et al.  Insight into analysis of interactions of GW9508 to wild-type and H86F and H137F GPR40: a combined QM/MM study and pharmacophore modeling. , 2011, Journal of molecular graphics & modelling.

[15]  Violeta I. Pérez-Nueno,et al.  Improving VEGFR-2 Docking-Based Screening by Pharmacophore Postfiltering and Similarity Search Postprocessing , 2011, J. Chem. Inf. Model..

[16]  Jian-Ping Zhou,et al.  Discovery of novel mGluR1 antagonists: a multistep virtual screening approach based on an SVM model and a pharmacophore hypothesis significantly increases the hit rate and enrichment factor. , 2011, Bioorganic & medicinal chemistry letters.

[17]  Toshimasa Tanaka,et al.  Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. , 2011, Journal of medicinal chemistry.

[18]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[19]  M. Hahn,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[20]  Yun-ping Zhou,et al.  Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists. , 2010, Bioorganic & medicinal chemistry letters.

[21]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[22]  N. Morgan,et al.  G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. , 2009, Biochemical pharmacology.

[23]  Thierry Langer,et al.  Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. , 2009, Journal of medicinal chemistry.

[24]  Sebastian Radestock,et al.  Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring , 2008, J. Chem. Inf. Model..

[25]  Stefano Costanzi,et al.  Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. , 2008, Journal of medicinal chemistry.

[26]  Stefano Costanzi,et al.  Identification of Residues Important for Agonist Recognition and Activation in GPR40* , 2007, Journal of Biological Chemistry.

[27]  B. Raaka,et al.  Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. , 2007, Journal of medicinal chemistry.

[28]  Songfeng Lu,et al.  Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists. , 2007, Journal of medicinal chemistry.

[29]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[30]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[31]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[32]  A. Goetz,et al.  Synthesis and activity of small molecule GPR40 agonists. , 2006, Bioorganic & medicinal chemistry letters.

[33]  Hongmao Sun,et al.  Enhancing Specificity and Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Chemical and Shape Features-A Case Study of HIV Protease Inhibitors , 2006, J. Chem. Inf. Model..

[34]  Andreas Evers,et al.  Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.

[35]  J. Pin,et al.  Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. , 2005, Journal of medicinal chemistry.

[36]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[37]  Masataka Harada,et al.  Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40 , 2003, Nature.

[38]  Teruki Honma,et al.  Combining Machine Learning and Pharmacophore-Based Interaction Fingerprint for in Silico Screening , 2010, J. Chem. Inf. Model..

[39]  Pang-Ning Tan,et al.  Receiver Operating Characteristic , 2009, Encyclopedia of Database Systems.

[40]  M. Prentki,et al.  Fatty acid signaling in the beta-cell and insulin secretion. , 2006, Diabetes.

[41]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..